Commit Sales Contribute To 25% Gain In GSK Smoking Cessation Sales In Q4
This article was originally published in The Tan Sheet
Executive Summary
Sales of GlaxoSmithKline's Commit nicotine polacrilex lozenge helped drive the company's fourth quarter smoking cessation sales to $198 mil., up 25% at constant exchange rates compared with the year-ago period